Skip to main content
SpringerLink
Log in

Pharmacological Management of Peyronie’s Disease

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Peyronie’s disease is a localised, fibrosing condition of the penis that occurs in up to 9% of men. Although its aetiology has not been elucidated, Peyronie’s disease probably results from the presence of a predisposing genetic susceptibility combined with an inciting event, most probably trauma. Following appropriate clinical evaluation, initial treatment consists of a trial of oral and/or intralesional pharmacotherapy. Oral therapies most commonly employed include para-aminobenzoate (Potaba®) and tocopherol (vitamin E), with colchicine, tamoxifen, propoleum and acetyl-L-carnitine being used less frequently. Placebo-controlled studies examining these agents have failed to show a consistent beneficial effect on Peyronie’s disease, with the exception of para-aminobenzoate, which may decrease plaque size and curvature, and acetyl-L-carnitine, which may reduce erectile pain and inhibit disease progression. Intralesional injection therapy for Peyronie’s disease is commonly used as a first-line therapy along with oral medications. The current standard of care involves injection with interferon-α-2a or -2b, verapamil or collagenase over 2-week intervals for a period of 5–6 months. Interferon-α-2b, in particular, has been documented in a large, multicentre, placebo-controlled study to be significantly more effective than placebo in decreasing penile curvature, plaque size, penile pain and plaque density. However, interferon treatment is also associated with significant adverse effects, including fever and other flu-like symptoms. Other available therapies that have not consistently shown efficacy in placebo-controlled studies include corticosteroids and orgotein. Surgery is considered in patients with Peyronie’s disease who have not responded to a trial of conservative medical therapy for 1 year and who are precluded from sexual intercourse. Procedures commonly performed include the Nesbit procedure (or variations of the Nesbit), penile plaque incision/excision with or without grafting, and implantation of a penile prosthesis. Further basic scientific research in Peyronie’s disease is likely to identify additional targets for future pharmacotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Williams JL, Thomas GG. The natural history of Peyronie’s disease. J Urol 1970 Jan; 103(1): 75–6

    PubMed  CAS  Google Scholar 

  2. Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol 1990 Dec; 144(6): 1376–9

    PubMed  CAS  Google Scholar 

  3. Kadioglu A, Tefekli A, Erol B, et al. A retrospective review of 307 men with Peyronie’s disease. J Urol 2002 Sep; 168(3): 1075–9

    Article  PubMed  Google Scholar 

  4. Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001 Nov; 88(7): 727–30

    Article  PubMed  CAS  Google Scholar 

  5. Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004 Jun; 171 (6 Pt 1): 2350–3

    Article  PubMed  Google Scholar 

  6. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol 2006 Jun; 175(6): 2115–8; discussion 2118

    Article  PubMed  Google Scholar 

  7. Bjekic MD, Vlajinac HD, Sipetic SB, et al. Risk factors for Peyronie’s disease: a case-control study. BJU Int 2006 Mar; 97(3): 570–4

    Article  PubMed  Google Scholar 

  8. Devine CJ Jr, Somers KD, Jordan SG, et al. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997 Jan; 157(1): 285–90

    Article  PubMed  Google Scholar 

  9. Zargooshi J. Trauma as the cause of Peyronie’s disease: penile fracture as a model of trauma. J Urol 2004 Jul; 172(1): 186–8

    Article  PubMed  Google Scholar 

  10. Qian A, Meals RA, Rajfer J, et al. Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 2004 Aug; 64(2): 399–404

    Article  PubMed  CAS  Google Scholar 

  11. Magee TR, Qian A, Rajfer J, et al. Gene expression profiles in the Peyronie’s disease plaque. Urology 2002 Mar; 59(3): 451–7

    Article  PubMed  Google Scholar 

  12. Davila HH, Ferrini MG, Rajfer J, et al. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int 2003 Jun; 91(9): 830–8

    Article  PubMed  CAS  Google Scholar 

  13. Haag SM, Hauck EK, Szardening-Kirchner C, et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie’s disease. Eur Urol 2007; 51(1): 255–61

    Article  PubMed  CAS  Google Scholar 

  14. Davila HH, Magee TR, Zuniga FI, et al. Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 2005 Apr; 65(4): 645–8

    Article  PubMed  Google Scholar 

  15. Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie’s disease. Int J Impot Res 2003; 15 (5 Suppl.): 103–2S

    Article  Google Scholar 

  16. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 Jun; 49(6): 822–30

    Article  PubMed  CAS  Google Scholar 

  17. Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie’s disease. Curr Opin Urol 2004 Nov; 14(6): 381–8

    Article  PubMed  Google Scholar 

  18. Traber MG. Vitamin E. In: Shils ME, Olson JA, Shike M, et al., editors. Modern nutrition in health and disease. 10th ed. Baltimore (MD): Williams & Wilkins, 1999: 347–62

    Google Scholar 

  19. Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie’s disease. Int J Impot Res 1999 Aug; 11(4): 207–12

    Article  PubMed  CAS  Google Scholar 

  20. Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie’s disease. Ann NY Acad Sci 1949; 52: 390–401

    Google Scholar 

  21. Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Biol 1983; 9: 41–5

    Google Scholar 

  22. Hashimoto K, Hisasue S, Kato R, et al. Outcome analysis for conservative management of Peyronie’s disease. Int J Urol 2006 Mar; 13(3): 244–7

    Article  PubMed  Google Scholar 

  23. Zarafonetis CJD, Horrax TM. Treatment of Peyronie’s disease with potassium para-aminobenzoate (Potaba). J Urol 1959; 81: 770–2

    PubMed  CAS  Google Scholar 

  24. Weidner W, Hauck EW, Schnitter J. Potassium paraami-nobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005 Apr; 47(4): 530–5; discussion E535-6

    Article  PubMed  CAS  Google Scholar 

  25. Hauck EW, Bschleipfer T, Haag SM, et al. Assessment among German urologists of various conservative treatment modalities for Peyronie’s disease: results of a survey [in German]. Urologe A 2005; 44: 1189–96

    Article  PubMed  CAS  Google Scholar 

  26. El-Sakka AI, Bakircioglu ME, Bhatnagar RS, et al. The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol 1999 Jun; 161(6): 1980–3

    Article  PubMed  CAS  Google Scholar 

  27. Kadioglu A, Tefekli A, Koksal T, et al. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000 Jun; 12(3): 169–75

    Article  PubMed  CAS  Google Scholar 

  28. Prieto Castro RM, Leva Vallejo ME, Requeiro JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int 2003 Apr; 91(6): 522–4

    Article  PubMed  CAS  Google Scholar 

  29. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004 Jun; 16(3): 238–43

    Article  PubMed  CAS  Google Scholar 

  30. Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992 Dec; 70(6): 648–51

    Article  PubMed  CAS  Google Scholar 

  31. Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999 Dec; 162(6): 2003–5

    Article  PubMed  CAS  Google Scholar 

  32. Lemourt OM, Filgueiras LE, Rodriguez BA, et al. Clinical evaluation of the use of propoleum in Peyronie’s disease [in Spanish]. Arch Esp Urol 1998; 51: 171–6

    Google Scholar 

  33. Lemourt OM, Rodriguez BA, Puente GM, et al. Propoleum and Peyronie’s disease [in Spanish]. Arch Esp Urol 2003; 56: 805–13

    Google Scholar 

  34. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 2001 Jul; 88(1): 63–7

    Article  PubMed  CAS  Google Scholar 

  35. Tranchant C, Braun S, Warter JM. Mechanism of action of glucocorticoids: role of lipocortins [in French]. Rev Neurol 1989; 145: 813–8

    PubMed  CAS  Google Scholar 

  36. Bodner H, Howard AH, Kaplan JH. Peyronie’s disease; cortisone-hyaluronidase-hydrocortisone therapy. Trans West Sect Am Urol Assoc 1953; 20: 32–5

    PubMed  CAS  Google Scholar 

  37. Winter CC, Khanna R. Peyronie’s disease: results with dermojet injection of dexamethasone. J Urol 1975 Dec; 114(6): 898–900

    PubMed  CAS  Google Scholar 

  38. Williams G, Green NA. The non-surgical treatment of Peyronie’s disease. Br J Urol 1980 Oct; 52(5): 392–5

    Article  PubMed  CAS  Google Scholar 

  39. Cipollone G, Nicolai M, Mastroprimiano G, et al. Betamethasone versus placebo in Peyronie’s disease [in Italian]. Arch Ital Urol Androl 1998; 70: 165–8

    PubMed  CAS  Google Scholar 

  40. Bartsch G, Menander-Huber KB, Huber W, et al. Orgotein, a new drug for the treatment of Peyronie’s disease. Eur J Rheumatol Inflamm 1981; 4(2): 250–9

    PubMed  CAS  Google Scholar 

  41. Gustafson H, Johansson B, Edsmyr F. Peyronie’s disease: experience of local treatment with orgotein. Eur Urol 1981; 7(6): 346–8

    PubMed  CAS  Google Scholar 

  42. Revelli G, Marino B, Piccoli F, et al. La Peyronie’s disease: our experience [in Italian]. Minerva Chir 1990; 45: 47–50

    PubMed  CAS  Google Scholar 

  43. Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie’s disease). Int Urol Nephrol 1993; 25(2): 169–72

    PubMed  CAS  Google Scholar 

  44. Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad Med J 2003; 79: 449–53

    Article  PubMed  CAS  Google Scholar 

  45. Gelbard M, Walsh R, Kaufman JJ. Clostridial collagenase and Peyronie disease [letter]. Urology 1980 May; 15(5): 536

    Article  PubMed  CAS  Google Scholar 

  46. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol 1985 Aug; 134(2): 280–3

    PubMed  CAS  Google Scholar 

  47. Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 1993 Jan; 149(1): 56–8

    PubMed  CAS  Google Scholar 

  48. Hamilton RG, Mintz GR, Gelbard MK: Humoral immune responses in Peyronie’s disease patients receiving clostridial collagenase therapy. J Urol 1986 Mar; 135(3): 641–7

    PubMed  CAS  Google Scholar 

  49. Roth M, Eickelberg O, Kohler E, et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996; 93: 5478–82

    Article  PubMed  CAS  Google Scholar 

  50. Mulhall JP, Anderson MS, Lubrano T, et al. Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397–405

    Article  PubMed  CAS  Google Scholar 

  51. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 1994 Jun; 151(6): 1522–4

    PubMed  CAS  Google Scholar 

  52. Arena F, Peracchia G, Di Stefano C, et al. Clinical effects of verapamil in the treatment of Peyronie’s disease [in Italian]. Acta Biomed Ateneo Parmense 1995; 66: 269–72

    PubMed  CAS  Google Scholar 

  53. Lasser A, Vandenberg TL, Vincent MJ, et al. Intraplaque verapamil injection for treatment of Peyronie’s disease. J La State Med Soc 1998 Sep; 150(9): 431–4

    PubMed  CAS  Google Scholar 

  54. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002 Aug; 168(2): 621–5; discussion 625-6

    Article  PubMed  CAS  Google Scholar 

  55. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 1998 Apr; 51(4): 620–6

    Article  PubMed  CAS  Google Scholar 

  56. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25(2): 89–94

    Article  PubMed  CAS  Google Scholar 

  57. Wegner HE, Andresen R, Knipsel HH, et al. Treatment of Peyronie’s disease with local interferon-alpha 2b. Eur Urol 1995; 28(3): 236–40

    PubMed  CAS  Google Scholar 

  58. Ahuja S, Bivalacqua TJ, Case J, et al. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl 1999 Jul–Aug; 20(4): 444–8

    PubMed  CAS  Google Scholar 

  59. Brake M, Loertzer H, Horsch R, et al. Treatment of Peyronie’s disease with local interferon-alpha 2b. BJU Int 2001 May; 87(7): 654–7

    Article  PubMed  CAS  Google Scholar 

  60. Astorga R, Cantero O, Contreras D, et al. Intralesional recombinant interferon alpha-2b in Peyronie’s disease. Arch Esp Urol. 2000 Sep; 53(7): 665–71

    PubMed  CAS  Google Scholar 

  61. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie’s disease: a pilot study. Br J Urol 1997 Jan; 79(1): 40–2

    Article  PubMed  CAS  Google Scholar 

  62. Polat O, Gul O, Ozbey I, et al. Peyronie’s disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol 1997; 29(4): 465–71

    Article  PubMed  CAS  Google Scholar 

  63. Dang G, Matern R, Bivalacqua TJ, et al. Intralesional interferon-alpha-2B injections for the treatment of Peyronie’s disease. South Med J 2004 Jan; 97(1): 42–6

    Article  PubMed  Google Scholar 

  64. Kendirci M, Usta MF, Matern RV, et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie’s disease. J Sex Med 2005 Sep; 2(5): 709–15

    Article  PubMed  CAS  Google Scholar 

  65. Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 2006 Jul; 176(1): 394–8

    Article  PubMed  CAS  Google Scholar 

  66. Wegner HE, Andresen R, Knispel HH, et al. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie’s disease. Eur Urol 1997; 32(2): 190–3

    PubMed  CAS  Google Scholar 

  67. Gelbard M, Lindner A, Chvapil M, et al. Topical beta-aminopropionitrile in the treatment of Peyronie’s disease. J Urol 1983; 129(4): 746–8

    PubMed  CAS  Google Scholar 

  68. Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology 1983; 21(6): 584–5

    Article  PubMed  CAS  Google Scholar 

  69. Martin DJ, Badwan K, Parker M, et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168(6): 2483–5

    Article  PubMed  CAS  Google Scholar 

  70. Schieroni MP, Revello MP, Colombo M, et al. Orgotein iontophoresis in the therapy of induratio penis plastica [in Italian]. Minerva Med 1985; 76(22–23): 1085–8

    PubMed  CAS  Google Scholar 

  71. Levine LA, Estrada CR, Shou W, et al. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003; 169(5): 1775–8

    Article  PubMed  CAS  Google Scholar 

  72. Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 2004; 171(4): 1605–8

    Article  PubMed  Google Scholar 

  73. Di Stasi SM, Giannantoni A, Capelli G, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int 2003; 91(9): 825–9

    Article  PubMed  Google Scholar 

  74. Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie’s disease. J Urol 1979 Nov; 122(5): 622–3

    PubMed  CAS  Google Scholar 

  75. Bystrom J, Alfthan O, Gustafson H, et al. Early and late results after excision and dermo-fat grafting for Peyronie’s disease. Prog Reprod Biol 1972; 9: 78–84

    Google Scholar 

  76. Austoni E, Colombo F, Mantovani F, et al. Chirurgia radicale e conservazione dell’erezione nella malattia di La Peyronie. Arch Ital Urol 1995; 67: 359–64

    CAS  Google Scholar 

  77. Kadioglu A, Tefekli A, Usta M, et al. Surgical treatment of Peyronie’s disease with incision and venous patch technique. Int J Impot Res 1999; 11: 75–81

    Article  PubMed  CAS  Google Scholar 

  78. El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie’s disease: part II. Outcome analysis. J Urol 1998; 160: 2050–3

    CAS  Google Scholar 

  79. Valente E, Vernet D, Ferrini M, et al. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9(4): 229–44

    Article  PubMed  CAS  Google Scholar 

  80. Minor TX, Lin G, Jad A, et al. The effect of pentoxifylline on cultured human tunical fibroblasts from patients with Peyronie’s disease [online abstract]. Available from URL: http://peyroniesassociation.org/abstracts/effests_of_pentoxifylline.html [Accessed 2007 Jan 18]

  81. Davila HH, Magee TR, Rajfer J, et al. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie’s disease. Biol Reprod 2004; 71(5): 1568–77

    Article  PubMed  CAS  Google Scholar 

  82. Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3(2): 111–5

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Section of Andrology, Department of Urology, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, SL-42, Louisiana, 70112, USA

    Landon W. Trost, Serap Gur &  Wayne J. G. Hellstrom

Authors
  1. Landon W. Trost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serap Gur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wayne J. G. Hellstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wayne J. G. Hellstrom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trost, L.W., Gur, S. & Hellstrom, W.J.G. Pharmacological Management of Peyronie’s Disease. Drugs 67, 527–545 (2007). https://doi.org/10.2165/00003495-200767040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767040-00004

Keywords

Search

Navigation